


09/102,865



COPY OF PAPERS  
ORIGINALLY FILED

page 1

**Substitute Pages**  
**Clean Set of All Pending Claims**

D 1  
1. (thrice amended) A substantially homogenous glycoprotein preparation, said glycoprotein having an immunoglobulin CH2 domain said CH2 domain having at least one N-linked oligosaccharide wherein the oligosaccharide is a G2 oligosaccharide and wherein the amount of said glycoprotein containing a G1 and G0 oligosaccharide in the preparation does not exceed 10% by weight of the preparation.

2. (reiterated) The composition of 1 claim wherein the glycoprotein is an antibody.

3. (reiterated) The composition of claim 2 wherein the antibody is a monoclonal antibody.

4. (reiterated) The composition of claim 3 wherein the antibody is an IgG.

5. (reiterated) The composition of claim 4 wherein the IgG is human IgG1.

6. (reiterated) The composition of claim 5 wherein the monoclonal antibody is selected from the group consisting of an anti-CD20 specific monoclonal antibody, an anti-HER2 specific monoclonal antibody, and anti-VEGF specific monoclonal antibody, and an anti-IgE specific monoclonal antibody.

7. (reiterated) The composition of claim 1 wherein the glycoprotein is an immunoadhesin.

8. (reiterated) The composition of claim 7 wherein the immunoadhesin is a tumor necrosis factor-immunoglobulin G1 chimera.

9. (reiterated) The composition of claim 1 wherein the glycoprotein is an antibody-immunoadhesin chimera.

25. (reiterated) A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

26. (reiterated) A pharmaceutical composition comprising the composition of claim 6 and a pharmaceutically acceptable carrier.

27. (reiterated) A pharmaceutical composition comprising the composition of claim 7 and a pharmaceutically acceptable carrier.

28. (reiterated) An article of manufacture, comprising:  
a container;  
a label on said container; and  
the composition of claim 1 contained within said container;

29. (reiterated) The article of claim 28 wherein the label  
on the container indicates that the composition can be used for  
the treatment of cancer.